Inside TSCA | EPA Unlikely to Ease Testing for Disinfectants along FDA’s Lines

Whether your products are used for medical purposes or used in homes and offices, our Food, Drug & Device/FDA and Environment, Land Use & Natural Resources teams highlight the key regulatory requirements that apply, what has changed, and what the FDA and EPA will be watching out for when products are marketed for use in the evolving coronavirus (COVID-19) pandemic. 

Alston & Bird has formed a working group to advise clients on the business and legal implications of the COVID-19 coronavirus.

Our Environment, Land Use & Natural Resources Group outlines the requirements of a new reporting and recordkeeping rule for PFAS, the types of entities that will be impacted, and the anticipated reporting deadlines.

Kevin Minoli comments on a California federal court order requiring the Environmental Protection Agency to amend its Chemical Data Reporting rule and how it will impact asbestos regulation.

Elise Paeffgen comments on the U.S. Environmental Protection Agency’s new pharmaceutical waste rule and its clarification regarding health care facilities that mange over-the-counter medications.